Praveen Prakhar

Dr. Praveen Prakhar

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MMMohan S. Maddur
Mohan S. Maddur
ESEmmanuel Stephen-Victor
Emmanuel Stephen-Victor
MDMrinmoy Das
Mrinmoy Das
PPPraveen Prakhar
Praveen Prakhar
VSVarun K. Sharma
Varun K. Sharma
Jagadeesh BAYRYJagadeesh BAYRY
Jagadeesh BAYRY
Intravenous immunoglobulin (IVIG) is a polyspecific pooled immunoglobulin G preparation and one of the commonly used therapeutics for autoimmune diseases including those of neurological origin. A recent report in murine model proposed that IVIG expands regulatory T (Treg) cells via induction of interleukin 33 (IL-33). However, translational insight on these observations is lacking. Ten newly diagnosed Guillain-Barré syndrome (GBS) patients were treated with IVIG at the rate of 0.4 g/kg for three to five consecutive days. Clinical evaluation for muscular weakness was performed by Medical Research Council (MRC) and modified Rankin scoring (MRS) system. Heparinized blood samples were collected before and 1, 2, and 4–5 weeks post-IVIG therapy. Peripheral blood mononuclear cells were stained for surface CD4 and intracellular Foxp3, IFN-γ, and tumor necrosis factor alpha (TNF-α) and were analyzed by flow cytometry. IL-33 and prostaglandin E2 in the plasma were measured by ELISA. The fold changes in plasma IL-33 at week 1 showed no correlation with the MRC and MRS scores at weeks 1, 2, and ≥4 post-IVIG therapy. Clinical recovery following IVIG therapy appears to be associated with Treg cell response. Contrary to murine study, there was no association between the fold changes in IL-33 at week 1 and Treg cell frequency at weeks 1, 2, and ≥4 post-IVIG therapy. Treg cell-mediated clinical response to IVIG therapy in GBS patients was associated with reciprocal regulation of effector T cells-expressing TNF-α. Treg cell expansion by IVIG in patients with autoimmune diseases lack correlation with IL-33. Treg cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to IVIG therapy.

8 November 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
PPPraveen Prakhar
Praveen Prakhar
JAJaylene Alvarez-DelValle
Jaylene Alvarez-DelValle
HKHilary Keller
Hilary Keller
ACAssiatu Crossman
Assiatu Crossman
XTXuguang Tai
Xuguang Tai
JPJung-Hyun Park
Jung-Hyun Park
Foxp3 + Tregs are potent immunosuppressive CD4 + T cells that are critical to maintain immune quiescence and prevent autoimmunity. Both the generation and maintenance of Foxp3 + Tregs depend on the cytokine IL-2. Hence, the expression of the IL-2 receptor α -chain (CD25) is not only considered a specific marker, but also a nonredundant requirement for Tregs. Here, we report that Foxp3 + Tregs in the small intestine (SI) epithelium, a critical barrier tissue, are exempt from such an IL-2 requirement, since they had dramatically downregulated CD25 expression, showed minimal STAT5 phosphorylation ex vivo, and were unable to respond to IL-2 in vitro. Nonetheless, SI epithelial Tregs survived and were present at the same frequency as in other lymphoid organs, and they retained potent suppressor function that was associated with high levels of CTLA-4 expression and the production of copious amounts of IL-10. Moreover, adoptive transfer experiments of Foxp3 + Tregs revealed that such IL-2–independent survival and effector functions were imposed by the SI epithelial tissue, suggesting that tissue adaptation is a mechanism that tailors the effector function and survival requirements of Foxp3 + Tregs specific to the tissue environment.